Vanda Sues FDA For ‘Cutting Corners’ On MSN’s Generic Hetlioz Approval
Patient Population For MSN’s Generic Tasimelteon Targeted In New US Suit
Looking to take the FDA to court again, Vanda Pharmaceuticals has sued the agency for the way in which it evaluated and approved MSN Pharmaceuticals’ generic version of its sleep-wake disorder drug Hetlioz.
![FDASignBldg21Entrance_1200x675](https://insights.citeline.com/resizer/v2/RYO3ZB7RHJIZFESM3DS5722YGM.jpg?smart=true&auth=fee18ff04655cf1e9d2e245335100fca3c6b475957776b22f7167fe9c1868026&width=700&height=394)